A view from the Center


Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

While some barriers remain, value-based contracting for drugs has clearly moved past the talking phase

by Sonal Shah, Senior Manager, Deloitte Center for Health Solutions, Deloitte Services LP

It’s been four years since the Deloitte Center for Health Solutions collaborated with the Network for Excellence in Health Innovation (NEHI) to discuss the implications of value-based care on pharmaceutical innovation. Back then, the idea of value-based contracting (VBC) for drugs hadn’t moved much beyond exploring the concept. While there were a few examples here and there,

Read more

Why improving inclusion and diversity in clinical trials should be a research priority

by Karen Taylor, Research Director, UK Centre for Health Solutions, Deloitte Services LP

Several weeks ago, I participated in a panel discussion on inclusion and diversity in clinical trials. My research for the event and the discussion that ensued led me to conclude that while there have been some improvements, the pharma industry continues to struggle to recruit enough trial participants from important demographic groups, especially women, racial and ethnic minorities,

Read more

Drug rebates will remain… but so will pressure to reduce drug prices and demonstrate value

by George van Antwerp, managing director, and Joseph M. Coppola, managing director, Life Sciences Commercial and Market Access, Deloitte Consulting LLP

On July 10, the White House abandoned efforts to eliminate safe-harbor protections for drug rebates in Medicare Part D and Medicaid managed care due to concerns that the change would lead to higher premiums for beneficiaries. (For background on this issue, see our previous blogs.) While the rebate issue is now off the table,

Read more

Back to the future: With increased scrutiny over price increases, the fundamentals of organic growth in biopharma are more important than ever

by Cameron McClearn, principal, and Tom Yang, principal, Deloitte Consulting LLP

Price increases. This is arguably the most discussed topic in the biopharmaceutical industry today. In January, biopharmaceutical manufacturers raised list prices on more than 250 products.1 In July, 20 companies increased the list prices for more than 40 prescription drugs by an average of 13 percent.2 But are annual price increases a sustainable mechanism for driving future growth in biopharma?

Read more

Safety first: Technology and analytics could help transform pharmacovigilance

by Kelly Traverso, Life Sciences R&D, Deloitte Consulting LLP

Sometimes a relatively small investment can lead to the development of a product or process that benefits a company, an industry, or even society as a whole. The three-point seat belt, for example, is a simple strap of nylon webbing that protects drivers and passengers from being injured in an accident. This innovation helped to transform safety standards in the automotive industry and has saved millions of lives.

Read more

Digital tech and strong patient-advocacy partnerships could be a win-win-win for pharma, advocacy groups, and patients

by Jonathan Fox, Specialist leader, Deloitte Consulting LLP

I’m in Philadelphia this week for the annual EyeForPharma conference where I’ll be moderating a panel looking into how pharmaceutical companies and advocacy groups can take their relationship to the next level. Both sides have something to gain, and the patient could be the biggest winner.

Pharmaceutical companies often collaborate with patient advocacy groups,

Read more